His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:6/3/2018
Start Date:May 17, 2016
End Date:June 2021
Contact:Gaurav A. Upadhyay, MD
Email:gupadhyay@medicine.bsd.uchicago.edu
Phone:773-702-5988

Use our guide to learn which trials are right for you!

The goal of this study is to compare the effectiveness of pacing from a physiologic His
bundle (HB) lead position versus with the standard coronary sinus (CS) lead position in
subjects with heart failure undergoing cardiac resynchronization therapy (CRT). While
placement of left ventricular leads via the coronary sinus has anatomic limitations, we
hypothesis that the achievement of QRS narrowing with His bundle capture will be superior for
improving systolic function by echocardiographic indices (ejection fraction and strain) and
quality of life and decreased rehospitalization and mortality.

This is a randomized, single-blinded study of 40 patients to a strategy of HB pacing versus
CS pacing, and remain blinded to their treatment allocation. Both treatment options use
standard-of-care, FDA-approved devices. The distinction is only in the allocation toward HB
pacing and CS pacing. Treating physicians will be aware of assignment in order to facilitate
routine device follow-up. Echocardiographic and electrocardiographic evaluation will also be
performed in a blinded manner.

Cross-over is permitted between treatment group allocation if:

- CS lead cannot be placed due to difficult cannulation of the CS, limited branches at the
posterolateral or lateral wall, or phrenic nerve capture. These subjects may then
cross-over to HB pacing.

- HB pacing subjects may cross-over if HB lead cannot be positioned with adequate
stability and reasonable pacing output, or if QRS width does not narrow by at least 20%
or to a QRS width of ≤ 130 msec.

Implant procedure will be per routine percutaneous access, as is standard for pacemaker and
ICDs. All subjects will receive an FDA-approved cardiac resynchronization therapy pacemaker
or defibrillator device, as per standard of care outlined for the subject. In order to
facilitate optimal lead placement, arterial access for levo-phase CS angiography and/or LV
septal mapping to characterize site of bundle-branch block may also be performed, at the
discretion of the implanting physician per his/her standard practice.

Follow-up will be performed at 2 weeks post-implant for incision check and device
interrogation as is standard of care. In addition, routine device and clinical follow-up will
be scheduled at 1, 3, 6, and 12 months. Electrocardiography (ECG) will be performed
pre-implant, prior to hospital discharge, at 3 months, 6 months, and 12 months.
Echocardiography will be performed pre-implant and 6 months to evaluate for change in LVEF,
chamber dimension, and wall motion with strain imaging as is standard of care in the
treatment of patients with advanced heart failure. NYHA functional class and quality of life
(utilizing the Kansas City Cardiomyopathy Questionnaire) will be assessed pre-implant and at
6 months.

Inclusion Criteria:

- Patients at least 18 years of age

- LV systolic dysfunction with LVEF ≤ 35%

- Evidence of intraventricular conduction delay with QRS duration > 120 msec

- NYHA Class II, III, and ambulatory Class IV heart failure with either ischemic or
nonischemic cardiomyopathy and patients with NYHA Class I symptoms and ischemic
cardiomyopathy

- Left ventricular ejection fraction (LVEF) ≤ 35%, sinus rhythm (SR), left bundle-branch
block (LBBB) morphology, and QRS duration ≥ 150 msec, and NYHA Class II, III, or
ambulatory Class IV patients on goal-directed medical therapy (GDMT) [Class I]

- LVEF ≤ 35%, SR with LBBB with QRS 120-149 msec on GDMT [Class IIa]

- LVEF ≤ 35%, SR with non-LBBB with QRS ≥ 150 msec on GDMT [Class IIa]

- LVEF ≤ 35%, in AF if medication or AV nodal ablation will allow near 100% pacing
[Class IIa]

- LVEF ≤ 35% undergoing new or replacement device with anticipated >40% ventricular
pacing on GDMT [Class IIa]

- LVEF ≤ 30%, ischemic etiology of HF, SR with LBBB ≥ 150 msec and NYHA Class I symptoms
on GDMT [Class IIb]

- LVEF ≤ 35%, SR with non-LBBB with QRS 120-149 msec, NYHA Class III/ambulatory Class IV
HF on GDMT [Class IIb] LVEF ≤ 35%, SR with non-LBBB with QRS ≥ 150 msec, NYHA Class II
HF on GDMT [Class IIb]

Exclusion Criteria:

- Existing CRT device

- Inability of patient capacity to provide consent for themselves either due to medical
or psychiatric comorbidity

- Pregnancy

- Participation in other trials

- Difficulty with follow-up
We found this trial at
8
sites
Los Angeles, California 90095
310-825-4321
Principal Investigator: Olujimi A. Ajijola, MD, PhD
Phone: 310-206-6433
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Gaurav A. Upadhyay, MD
Phone: 773-702-5988
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Principal Investigator: Gopi Dandamudi, MD
Phone: 317-962-0500
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Phone: 312-695-4965
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Phone: 312-942-0182
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Louisville, Kentucky 40207
Principal Investigator: John Mandrola, MD
Phone: 502-893-7710
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Naperville, Illinois 60566
Principal Investigator: Moeen A. Saleem, MD
?
mi
from
Naperville, IL
Click here to add this to my saved trials
Wilkes-Barre, Pennsylvania 18711
Phone: 570-808-6020
?
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials